'Additional properties' signal promise of Mitsubishi Tanabe's out-licensed CETP inhibitor
This article was originally published in Scrip
Executive Summary
Mitsubishi Tanabe Pharma has out-licensed a clinical-stage cholesteryl ester transfer protein (CETP) inhibitor to a young Dutch biotech firm, Dezima Pharma.